# Abbisko Therapeutics Co, Ltd clinical trials: 38 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 38 trials with Abbisko Therapeutics Co, Ltd as lead sponsor, 15 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Abbisko Therapeutics Co, Ltd: 38 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/abbisko-therapeutics-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 38
- Recruiting or not yet: 15
- Read on: November 19, 2026

## Trials

The 25 newest of 38, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 21, 2026 | NCT07718165 | A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration | Abbisko Therapeutics Co, Ltd | Phase 1 | Recruiting | Solid Tumor (Phase I) | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718165) |
| July 17, 2026 | NCT07710612 | A Phase 2 Study of ABSK043 Combined With Osimertinib | Abbisko Therapeutics Co, Ltd | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710612) |
| July 14, 2026 | NCT07700953 | A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011... | Abbisko Therapeutics Co, Ltd | Phase 1 | Recruiting | Healthy Participants | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700953) |
| February 18, 2026 | NCT07417189 | A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) | Abbisko Therapeutics Co, Ltd | Phase 1/2 | Recruiting | Solid Tumors, Adult | 401 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07417189) |
| January 8, 2026 | NCT07327034 | ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | Abbisko Therapeutics Co, Ltd | Phase 2 | Recruiting | Hepatocellular Carcinoma (HCC) | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07327034) |
| December 24, 2025 | NCT07301463 | A Study in Children With Achondroplasia | Abbisko Therapeutics Co, Ltd | Observational | Recruiting | Achondroplasia | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301463) |
| December 22, 2025 | NCT07297875 | A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia | Abbisko Therapeutics Co, Ltd | Phase 1/2 | Not yet recruiting | Achondroplasia | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297875) |
| December 17, 2025 | NCT07288957 | A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors | Abbisko Therapeutics Co, Ltd | Phase 1 | Recruiting | Solid Tumors (Phase 1) | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288957) |
| October 7, 2025 | NCT07210996 | A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects | Abbisko Therapeutics Co, Ltd | Phase 1 | Completed | Pharmacokinetics in Healthy Volunteers | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07210996) |
| September 10, 2025 | NCT07164170 | A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib | Abbisko Therapeutics Co, Ltd | Phase 2 | Recruiting | Non-Small Cell Lung Cancer | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07164170) |
| August 17, 2025 | NCT07126249 | A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy Subjects | Abbisko Therapeutics Co, Ltd | Phase 1 | Completed | Pharmacokinetics | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07126249) |
| June 6, 2025 | NCT07007546 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants | Abbisko Therapeutics Co, Ltd | Phase 1 | Completed | Healthy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07007546) |
| March 26, 2025 | NCT06896760 | A Mass Balance Study of \[14C\]ABSK011 | Abbisko Therapeutics Co, Ltd | Phase 1 | Not yet recruiting | Healthy Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06896760) |
| March 19, 2025 | NCT06884072 | A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects | Abbisko Therapeutics Co, Ltd | Phase 1 | Active not recruiting | Healthy Subjects | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06884072) |
| January 16, 2025 | NCT06779253 | A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects | Abbisko Therapeutics Co, Ltd | Phase 1 | Completed | Healthy Subjects | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06779253) |
| November 19, 2024 | NCT06694948 | A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects | Abbisko Therapeutics Co, Ltd | Phase 1 | Completed | Pharmacokinetics | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06694948) |
| October 31, 2024 | NCT06668103 | A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib | Abbisko Therapeutics Co, Ltd | Phase 2 | Recruiting | Non-Small Cell Lung Cancer With EGFR Mutation | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06668103) |
| October 9, 2024 | NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | Abbisko Therapeutics Co, Ltd | Phase 2 | Recruiting | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06632262) |
| August 20, 2024 | NCT06562946 | The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With... | Abbisko Therapeutics Co, Ltd | Phase 1 | Completed | Pharmacokinetics | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06562946) |
| March 21, 2024 | NCT06322706 | A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021 | Abbisko Therapeutics Co, Ltd | Phase 1 | Completed | Healthy Subjects | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06322706) |
| March 12, 2024 | NCT06306872 | A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules | Abbisko Therapeutics Co, Ltd | Phase 1 | Completed | Healthy Subjects | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06306872) |
| January 26, 2024 | NCT06225804 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer | Abbisko Therapeutics Co, Ltd | Phase 1 | Active not recruiting | Non-Small Cell Lung Cancer | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06225804) |
| January 2, 2024 | NCT06186804 | A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease... | Abbisko Therapeutics Co, Ltd | Phase 2 | Enrolling by invitation | cGvHD | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06186804) |
| January 2, 2024 | NCT06186583 | A Mass Balance Study of \[14C\]ABSK021 | Abbisko Therapeutics Co, Ltd | Phase 1 | Completed | Healthy Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06186583) |
| November 1, 2023 | NCT06111274 | A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | Abbisko Therapeutics Co, Ltd | Phase 2 | Recruiting | Advanced Pancreatic Cancer | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06111274) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 23 |
| Phase 1/2 | 4 |
| Phase 2 | 9 |
| Phase 3 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 12 |
| Recruiting | 12 |
| Active not recruiting | 5 |
| Unknown | 4 |
| Not yet recruiting | 3 |
| Enrolling by invitation | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Transitional Cell | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Neoplasms | 3 |
| Giant Cell Tumor of Tendon Sheath | 2 |
| Achondroplasia | 2 |
| Carcinoma, Hepatocellular | 2 |
| Triple Negative Breast Neoplasms | 1 |
| Synovitis, Pigmented Villonodular | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cleaning products suppliers in the United States](https://specstream.ai/data/businesses/cleaning-products-suppliers/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
- [Family practice clinics in the United States](https://specstream.ai/data/businesses/family-practice-clinics/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [Beauty product suppliers in the United States](https://specstream.ai/data/businesses/beauty-product-suppliers/united-states)
